Overall, 32.97% of patients from the BRAF and MEK inhibitor treatment group had risk of rash compared with 38.40% in the control group, and 10.3% of patients in the BRAF and MEK treatment group developed alopecia, compared with 37.59% in the BRAF inhibitor control group. Here, MAP2K7 is linked to exanthem.